A. Kerber

Learn More
INTRODUCTION This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins αVβ3 and αVβ5, with that of docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). METHODS Patients (n = 140) with advanced NSCLC who had failed(More)
  • 1